STAT+: Pharmalittle: We’re reading about pharma lobbying, a disappointing Novo clinical trial, and much more

Pharmaceutical companies are increasing their expenditures on lobbying firms that have connections to the White House. This trend reflects a broader strategy within the industry to influence policy and regulatory decisions that may impact their operations and profitability. The heightened spending on lobbying comes amid ongoing discussions about drug pricing and healthcare reform in the United States. In a related context, President Trump, during his State of the Union address, asserted that his administration had successfully reduced U.S. prescription drug costs from the highest in the world to the lowest. This claim highlights the administration's focus on drug pricing as a key issue, although the accuracy of such statements has been a topic of debate among experts and analysts. Additionally, the Trump administration has released detailed guidance aimed at facilitating the approval of bespoke medicines designed to treat individual patient mutations. This initiative is part of a broader effort to address the needs of patients with ultra-rare diseases, potentially expanding the market for pharmaceutical companies involved in developing personalized medicine. Furthermore, Novo Nordisk has been noted for cutting prices on its GLP-1 drugs, which are used for obesity treatment. This move may be part of a competitive strategy in response to the evolving landscape of drug pricing and healthcare policies under the current administration.